Truist Resumes Coverage on PTC Therapeutics (PTCT) with Hold, Citing Growth Concerns

gurufocus.com · 2026-10-16

On October 16, 2026, Truist analyst Joon Lee resumed coverage of PTC Therapeutics Inc (NASDAQ: PTCT) with a Hold rating and a price target of $62. The firm expr

Read the full story at gurufocus.com →